{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:04:07Z","timestamp":1787007847044,"version":"build-2736575974"},"reference-count":66,"publisher":"Rockefeller University Press","issue":"3","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA042014"],"award-info":[{"award-number":["P30 CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30 CA235964"],"award-info":[{"award-number":["F30 CA235964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA131261"],"award-info":[{"award-number":["R01 CA131261"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA176839"],"award-info":[{"award-number":["R01 CA176839"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA230151"],"award-info":[{"award-number":["K08 CA230151"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HCI Preclinical Research Shared Resource"},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","award":["SU2C-AACR-PCC-04-18"],"award-info":[{"award-number":["SU2C-AACR-PCC-04-18"]}],"id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010637","name":"Huntsman Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010637","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Huntsman GI Disease Center"},{"DOI":"10.13039\/100004319","name":"Pfizer Consumer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Five for the Fight"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,6]]},"abstract":"<jats:p>Pharmacological inhibition of KRAS&amp;gt;RAF&amp;gt;MEK1\/2&amp;gt;ERK1\/2 signaling has provided no clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly, combined inhibition of MEK1\/2 (with trametinib [T]) plus autophagy (with chloroquine [CQ] or hydroxychloroquine [HCQ]) demonstrated striking anti-tumor effects in preclinical models and in a patient (Patient 1). However, not all patients respond to the T\/HCQ regimen, and Patient 1 eventually developed resistant disease. Here we report that primary or acquired resistance is associated with focal DNA copy number gains encompassing c-MYC. Furthermore, ectopic expression of c-MYC in PDAC cell lines rendered them T\/HCQ resistant. Interestingly, a CDK4\/6 inhibitor, palbociclib (P), also induced autophagy and overrode c-MYC\u2013mediated T\/HCQ resistance, such that P\/HCQ promoted regression of T\/HCQ-resistant PDAC tumors with elevated c-MYC expression. Finally, P\/HCQ treatment of Patient 1 resulted in a biochemical disease response. These data suggest that elevated c-MYC expression is both a marker and a mediator of T\/HCQ resistance, which may be overcome by the use of P\/HCQ.<\/jats:p>","DOI":"10.1084\/jem.20221524","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:21:03Z","timestamp":1671589263000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4\/6 and lysosomal inhibition"],"prefix":"10.1084","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-1983","authenticated-orcid":true,"given":"Mark R.","family":"Silvis","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-1744","authenticated-orcid":true,"given":"Dilru","family":"Silva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"},{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncological Sciences, University of Utah 2 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-1069","authenticated-orcid":true,"given":"Riley","family":"Rohweder","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-9016","authenticated-orcid":true,"given":"Sophia","family":"Schuman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-2285","authenticated-orcid":true,"given":"Swapna","family":"Gudipaty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00c2tyx86","id-type":"ROR","asserted-by":"publisher"}],"name":"ARUP Laboratories 3 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-5418","authenticated-orcid":true,"given":"Amanda","family":"Truong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009c06z12","id-type":"ROR","asserted-by":"publisher"}],"name":"Intermountain Medical Center 4 , Murray, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-2860","authenticated-orcid":true,"given":"Jeffrey","family":"Yap","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"},{"name":"Department of Radiology, University of Utah 5 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-0535","authenticated-orcid":true,"given":"Kajsa","family":"Affolter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"},{"name":"Department of Pathology, University of Utah 6 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-1042","authenticated-orcid":true,"given":"Martin","family":"McMahon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"},{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Oncological Sciences, University of Utah 2 , Salt Lake City, UT, USA"},{"name":"Department of Dermatology, University of Utah 7 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5614-8627","authenticated-orcid":true,"given":"Conan","family":"Kinsey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute, University of Utah 1 , Salt Lake City, UT, USA"},{"name":"Department of Internal Medicine, Division of Oncology, University of Utah 8 , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"2023013115045252000_bib1","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov."},{"key":"2023013115045252000_bib2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","volume":"3","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"2023013115045252000_bib3","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood.v95.6.2104","article-title":"c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover","volume":"95","author":"Bahram","year":"2000","journal-title":"Blood"},{"key":"2023013115045252000_bib4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191805","article-title":"Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer","volume":"217","author":"Bhattacharyya","year":"2020","journal-title":"J. Exp. Med."},{"key":"2023013115045252000_bib5","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1093\/emboj\/18.19.5321","article-title":"Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27","volume":"18","author":"Bouchard","year":"1999","journal-title":"EMBO J."},{"key":"2023013115045252000_bib6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1210\/jcem.86.1.7105","article-title":"Human pancreatic adenocarcinomas express parathyroid hormone-related protein","volume":"86","author":"Bouvet","year":"2001","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"2023013115045252000_bib7","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1073\/pnas.95.8.4344","article-title":"Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero","volume":"95","author":"Brandeis","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013115045252000_bib8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbagrm.2014.03.013","article-title":"Myc and cell cycle control","volume":"1849","author":"Bretones","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"2023013115045252000_bib9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"2023013115045252000_bib10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.4161\/cc.20718","article-title":"Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production","volume":"11","author":"Capparelli","year":"2012","journal-title":"Cell Cycle"},{"key":"2023013115045252000_bib11","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1158\/0008-5472.CAN-16-0425","article-title":"Cyclin D1 restrains oncogene-induced autophagy by regulating the AMPK-LKB1 signaling Axis","volume":"77","author":"Casimiro","year":"2017","journal-title":"Cancer Res."},{"key":"2023013115045252000_bib12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1073\/pnas.95.3.1091","article-title":"Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)","volume":"95","author":"Cheng","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013115045252000_bib13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","article-title":"The c-Myc target gene network","volume":"16","author":"Dang","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"2023013115045252000_bib14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat. Med."},{"key":"2023013115045252000_bib15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","article-title":"Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment","volume":"10","author":"Dey","year":"2020","journal-title":"Cancer Discov."},{"key":"2023013115045252000_bib17","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41467-017-01967-6","article-title":"MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance","volume":"8","author":"Farrell","year":"2017","journal-title":"Nat. Commun."},{"key":"2023013115045252000_bib18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cyto.990010114","article-title":"A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry","volume":"1","author":"Fox","year":"1980","journal-title":"Cytometry"},{"key":"2023013115045252000_bib19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.celrep.2015.12.094","article-title":"Metabolic reprogramming of pancreatic cancer mediated by CDK4\/6 inhibition elicits unique vulnerabilities","volume":"14","author":"Franco","year":"2016","journal-title":"Cell Rep."},{"key":"2023013115045252000_bib20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.4161\/auto.29394","article-title":"Sorting cells for basal and induced autophagic flux by quantitative ratiometric flow cytometry","volume":"10","author":"Gump","year":"2014","journal-title":"Autophagy"},{"key":"2023013115045252000_bib21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1101\/gad.283416.116","article-title":"Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells","volume":"30","author":"Guo","year":"2016","journal-title":"Genes Dev."},{"key":"2023013115045252000_bib22","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/0008-5472.CAN-04-2848","article-title":"Pharmacologic inhibition of RAF--&gt;MEK--&gt;ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1","volume":"65","author":"Gysin","year":"2005","journal-title":"Cancer Res."},{"key":"2023013115045252000_bib23","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1158\/1541-7786.MCR-12-0188","article-title":"Analysis of mRNA profiles after MEK1\/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity","volume":"10","author":"Gysin","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"2023013115045252000_bib24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2023013115045252000_bib25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2015.11.011","article-title":"Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression","volume":"29","author":"Hayes","year":"2016","journal-title":"Cancer Cell"},{"key":"2023013115045252000_bib26","first-page":"742","article-title":"Expression and prognostic value of c-Myc and Fas (CD95\/APO1) in patients with pancreatic cancer","volume":"7","author":"He","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"2023013115045252000_bib27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"key":"2023013115045252000_bib28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/onc.2015.216","article-title":"MYC in pancreatic cancer: Novel mechanistic insights and their translation into therapeutic strategies","volume":"35","author":"Hessmann","year":"2016","journal-title":"Oncogene"},{"key":"2023013115045252000_bib29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nrm2510","article-title":"Cyclin-dependent kinases and cell-cycle transitions: Does one fit all?","volume":"9","author":"Hochegger","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2023013115045252000_bib30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2023013115045252000_bib67","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"2023013115045252000_bib31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"2023013115045252000_bib32","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/s41467-020-17996-7","article-title":"Use of ratiometrically designed nanocarrier targeting CDK4\/6 and autophagy pathways for effective pancreatic cancer treatment","volume":"11","author":"Ji","year":"2020","journal-title":"Nat. Commun."},{"key":"2023013115045252000_bib33","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"2023013115045252000_bib34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"2023013115045252000_bib35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF--&gt;MEK--&gt;ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"2023013115045252000_bib36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","article-title":"Functional determinants of cell-cycle plasticity and sensitivity to CDK4\/6 inhibition","volume":"81","author":"Kumarasamy","year":"2021","journal-title":"Cancer Res."},{"key":"2023013115045252000_bib37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/304596a0","article-title":"Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes","volume":"304","author":"Land","year":"1983","journal-title":"Nature"},{"key":"2023013115045252000_bib38","doi-asserted-by":"publisher","first-page":"20608","DOI":"10.1074\/jbc.271.34.20608","article-title":"Cyclin D1 expression is regulated positively by the p42\/p44MAPK and negatively by the p38\/HOGMAPK pathway","volume":"271","author":"Lavoie","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2023013115045252000_bib39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/ncb1537","article-title":"The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis","volume":"9","author":"Liang","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"2023013115045252000_bib40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.devcel.2010.05.005","article-title":"A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions","volume":"18","author":"Lipinski","year":"2010","journal-title":"Dev. Cell"},{"key":"2023013115045252000_bib41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/gcc.10122","article-title":"Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer","volume":"35","author":"Mahlamaki","year":"2002","journal-title":"Genes Chromosome Cancer"},{"key":"2023013115045252000_bib42","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-19-0708","article-title":"CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival","volume":"79","author":"Mart\u00ednez-Carreres","year":"2019","journal-title":"Cancer Res."},{"key":"2023013115045252000_bib43","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/0046-8177(92)90399-n","article-title":"Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia","volume":"23","author":"Miraliakbari","year":"1992","journal-title":"Hum. Pathol."},{"key":"2023013115045252000_bib44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ng0197-83","article-title":"Delayed early embryonic lethality following disruption of the murine cyclin A2 gene","volume":"15","author":"Murphy","year":"1997","journal-title":"Nat. Genet."},{"key":"2023013115045252000_bib45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"2023013115045252000_bib46","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/1541-7786.MCR-19-0191","article-title":"The sustained induction of c-MYC drives Nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells","volume":"17","author":"Parasido","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"2023013115045252000_bib47","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/sj.onc.1201197","article-title":"Myc activation of cyclin E\/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes","volume":"14","author":"Perez-Roger","year":"1997","journal-title":"Oncogene"},{"key":"2023013115045252000_bib48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jcp.20816","article-title":"Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression","volume":"210","author":"Qi","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"2023013115045252000_bib49","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"2023013115045252000_bib50","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1158\/2159-8290.CD-22-0044","article-title":"Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer","volume":"12","author":"Ravichandran","year":"2022","journal-title":"Cancer Discov."},{"key":"2023013115045252000_bib51","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.celrep.2020.03.068","article-title":"Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1","volume":"31","author":"Romero-Pozuelo","year":"2020","journal-title":"Cell Rep."},{"key":"2023013115045252000_bib52","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-131","DOI":"10.12688\/f1000research.21981.1","article-title":"Recent advances in the treatment of pancreatic cancer","volume":"9","author":"Roth","year":"2020","journal-title":"F1000Res."},{"key":"2023013115045252000_bib53","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1038\/s41467-018-07472-8","article-title":"Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis","volume":"9","author":"Santana-Codina","year":"2018","journal-title":"Nat. Commun."},{"key":"2023013115045252000_bib54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235573","article-title":"Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels","volume":"15","author":"Sato","year":"2020","journal-title":"PLoS One"},{"key":"2023013115045252000_bib55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/modpathol.3880547","article-title":"c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: Incidence, mechanisms, and clinical significance","volume":"15","author":"Schleger","year":"2002","journal-title":"Mod. Pathol."},{"key":"2023013115045252000_bib56","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev."},{"key":"2023013115045252000_bib57","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/1535-7163.MCT-16-0867","article-title":"U1 adaptors suppress the KRAS-MYC oncogenic Axis in human pancreatic cancer xenografts","volume":"16","author":"Tsang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"2023013115045252000_bib58","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","article-title":"KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism","volume":"34","author":"Vaseva","year":"2018","journal-title":"Cancer Cell"},{"key":"2023013115045252000_bib59","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: An interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"2023013115045252000_bib60","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.semcancer.2006.07.015","article-title":"The Myc oncoprotein as a therapeutic target for human cancer","volume":"16","author":"Vita","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"2023013115045252000_bib61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature22797","article-title":"The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival","volume":"546","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"2023013115045252000_bib62","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"2023013115045252000_bib63","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2023013115045252000_bib64","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1634\/theoncologist.2014-0086","article-title":"Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma","volume":"19","author":"Wolpin","year":"2014","journal-title":"Oncologist"},{"key":"2023013115045252000_bib65","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12029-020-00556-z","article-title":"Trametinib and hydroxychloroquine (HCQ) combination treatment in KRAS-mutated advanced pancreatic adenocarcinoma: Detailed Description of two cases","volume":"52","author":"Xavier","year":"2021","journal-title":"J. Gastrointestinal Cancer"},{"key":"2023013115045252000_bib66","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1101\/gad.2016111","article-title":"Pancreatic cancers require autophagy for tumor growth","volume":"25","author":"Yang","year":"2011","journal-title":"Genes Dev."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20221524\/1447177\/jem_20221524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20221524\/1447177\/jem_20221524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T10:09:05Z","timestamp":1675159745000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/220\/3\/e20221524\/213844\/MYC-mediated-resistance-to-trametinib-and-HCQ-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,6]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20221524","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"article-number":"e20221524"}}